Indivior PLC stock (GB00BYZ0C031): opioid treatment specialist updates investors after US listing move

Indivior PLC has reshaped its capital market profile with a move to a primary US listing and continues to report solid demand for its addiction-treatment portfolio. What matters now for investors following the latest trading updates and strategic plans?

Indivior PLC is back in the spotlight as the specialist in addiction treatment continues to execute its strategy focused on the US market, following its move to a primary listing on Nasdaq and recent trading updates that underline ongoing demand for its opioid use disorder therapies, according to Indivior press releases as of 03/07/2024 and Reuters as of 03/07/2024.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Indivior
• Sector/industry: Pharmaceuticals, addiction treatment
• Headquarters/country: Richmond, Virginia, United States
• Core markets: United States, selected international markets
• Key revenue drivers: Opioid use disorder therapies such as Suboxone, Sublocade and related treatments
• Home exchange/listing venue: Nasdaq (ticker: INDV)
• Trading currency: USD

Indivior PLC: core business model

Indivior focuses on medicines for substance use disorders, with a particular emphasis on opioid dependence, which remains a major public health challenge in the United States. The company’s portfolio includes treatments designed to support long-term recovery and reduce misuse risks, according to Indivior company information as of 02/20/2024.

The business model is centered on prescription pharmaceuticals that target the brain’s opioid receptors to reduce cravings and withdrawal symptoms. Indivior generates revenue primarily from its branded therapies, which are marketed to healthcare providers, treatment centers and government-funded programs involved in addiction care in the US and other markets.

Beyond product sales, the company invests in clinical research designed to extend the lifecycle of its therapies and develop new formulations with longer-acting profiles. These efforts aim to support adherence and outcomes in real-world treatment settings, while also differentiating Indivior’s portfolio within a competitive landscape of generics and branded rivals.

Indivior’s US focus is reinforced by close engagement with payers, including Medicaid and commercial insurers, which play a critical role in reimbursement for opioid use disorder medicines. The company’s ability to maintain coverage and formulary positioning is a key factor for prescription volumes and overall revenue performance.

Main revenue and product drivers for Indivior PLC

Indivior’s revenue base is led by its injectable therapy Sublocade, which is designed as a long-acting treatment for moderate to severe opioid use disorder. The product has been a central growth driver in recent years, benefiting from prescriber adoption and guidelines that support long-acting options in addiction care, according to Indivior full year 2023 results as of 02/15/2024.

Legacy sublingual products, including formulations originally marketed under the Suboxone brand, continue to contribute to sales but face competition from generic alternatives. This has encouraged Indivior to shift its portfolio mix toward differentiated, patent-protected therapies, particularly in the US, where payers are sensitive to costs and generic substitution.

In its full year 2023 report, published in February 2024, Indivior highlighted that net revenue growth was driven primarily by increased Sublocade prescriptions in the United States, alongside contributions from other addiction-treatment products and geographic expansion initiatives. The company described continued investment in sales infrastructure and medical education to support uptake in community treatment settings.

Future growth potential for Indivior also depends on pipeline candidates and possible label expansions in areas such as alcohol use disorder and other substance-related conditions. Management has indicated that research and development spending remains an important allocation of capital, aiming to build a broader addiction-focused portfolio, as referenced in the 2023 annual filing summarized by SEC filings as of 03/15/2024.

Industry trends and competitive position

The addiction-treatment market is shaped by the ongoing opioid crisis in the United States, where federal and state initiatives support expanded access to medication-assisted treatment. This structural demand underpins Indivior’s focus on opioid use disorder therapies, but also brings scrutiny over pricing and promotional practices, as noted in coverage by Financial Times as of 01/30/2024.

Indivior competes with both branded peers and generic manufacturers offering buprenorphine-based therapies and alternative treatments. Competitive dynamics are influenced by clinical data, mode of administration, duration of effect and payer contracts. Long-acting injectables such as Sublocade are positioned as differentiated options that may help reduce diversion and non-medical use compared with some oral formulations.

Regulation is another decisive factor. US agencies oversee drug approval, post-marketing commitments and compliance with risk evaluation and mitigation strategies. Indivior must continuously meet these obligations while also addressing broader stakeholder expectations related to corporate responsibility in the context of the opioid epidemic.

Why Indivior PLC matters for US investors

For US investors, Indivior represents a focused play on the intersection of healthcare, public policy and the long-running response to opioid misuse. With its primary listing on Nasdaq, the stock is directly accessible to US-based portfolios and can feature in sector and thematic strategies tied to pharmaceuticals and behavioral health, according to Nasdaq market data as of 03/07/2024.

The company’s revenue is heavily concentrated in the United States, meaning earnings are closely linked to US healthcare utilization trends, reimbursement policies and the evolution of opioid treatment guidelines. Investors watching Indivior are therefore also monitoring legislative debates, funding decisions for treatment programs and shifts in clinical practice.

Because addiction treatment spans public and private payers, the company’s performance may respond to changes in Medicaid expansion, managed care contracts and government purchasing. This makes Indivior’s quarterly and annual updates a regular reference point for investors trying to gauge how policy developments translate into prescription volumes and pricing.

Conclusion

Indivior PLC has positioned itself as a specialist in opioid use disorder treatment, with its growth strategy increasingly centered on long-acting therapies and a primary focus on the US healthcare system. Recent financial disclosures underline the importance of Sublocade as a key revenue engine, alongside ongoing efforts to manage legacy product erosion and generic competition. For investors, the stock reflects both the opportunities of a structurally supported treatment market and the complexities of operating amid regulatory scrutiny and evolving public health policies. The balance between pipeline progress, market access, legal and compliance developments, and broader policy trends will likely remain central to how the market values Indivior over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.